Abstract

Monkeypox is a rare viral disease that has been identified as a potentially emerging infectious disease with the potential to cause outbreaks and epidemics. The virus is closely related to the small pox virus and belongs to the family Poxviridae. Monkey pox is primarily found in Central and West Africa, where it is transmitted to humans through contact with infected animals or humans. The virus can cause a range of clinical manifestations, from mild flu-like symptoms to severe illness with high mortality rates. The clinical presentation of monkey pox typically starts with fever, headache, muscle aches, and fatigue, followed by the development of a rash that spreads across the body. The rash progresses from macules to papules, vesicles, pustules, and scabs over several weeks. In severe cases, complications such as pneumonia, sepsis, and encephalitis can occur. There is currently no specific treatment for monkeypox. Supportive care measures such as hydration and pain management are used to manage symptoms and prevent complications. Vaccination against smallpox has been shown to provide some protection against monkeypox; however, it's effectiveness against the virus remains unclear. The prevention of monkeypox relies on measures such as avoiding contact with infected animals or humans and practicing good hygiene practices such as hand washing. Early detection of cases through surveillance systems is also crucial for preventing outbreaks. In conclusion, monkeypox is an emerging infectious disease that poses a significant public health threat in endemic regions. Continued research efforts are needed to better understand the epidemiology and pathogenesis of the virus and develop effective prevention strategies such as vaccines or antiviral therapies.

• 1.   C. E. Activity, “Monkeypox,” 2022.
• 2.   F. Fenner, “Epidemiology and Evolution,” Med. Microbiol., pp. 1–29, 1996, [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/21413273.
• 3.   I. Africa, “Monkeypox Virus Common Human Exposure Routes: Disease Agent Characteristics: Disease Name: Priority Level: Background:,” pp. 130–132, 2003.
• 4.   A. Alkhalil, S. Strand, E. Mucker, J. W. Huggins, P. B. Jahrling, and S. M. Ibrahim, “Inhibition of Monkeypox virus replication by RNA interference,” Virol. J., vol. 6, pp. 4–13, 2009, doi: 10.1186/1743- 422X-6-188.
• 5.   S. N. Shchelkunov et al., “Analysis of the monkeypox virus genome,” Virology, vol. 297, no. 2, pp. 172– 194, 2002, doi: 10.1006/viro.2002.1446.
• 6.   V. Strain et al., “crossm Identification and WholeGenome Sequencing of a Monkeypox,” no. December 2019, pp. 5–6, 2020.
• 7.   J. G. Bartlett, “The detection of monkeypox in humans in the western hemisphere,” Infectious Diseases in Clinical Practice, vol. 12, no. 4. pp. 275– 276, 2004, doi: 10.1097/01.idc.0000130890.12611.f3.
• 8.   C. K. Ellis et al., “Ecology and geography of human monkeypox case occurrences across Africa,” J. Wildl. Dis., vol. 48, no. 2, pp. 335–347, 2012, doi: 10.7589/0090-3558-48.2.335.
• 9.   Y. Li, H. Zhao, K. Wilkins, C. Hughes, and I. K. Damon, “Real-time PCR assays for the specific detection of monkeypox virus West African and Congo Basin strain DNA,” J. Virol. Methods, vol. 169, no. 1, pp. 223–227, 2010, doi: 10.1016/j. jviromet.2010.07.012.
• 10.   K. H. Rubins, L. E. Hensley, D. A. Relman, and P. O. Brown, “Stunned silence: Gene expression programs in human cells infected with monkeypox or vaccinia virus,” PLoS One, vol. 6, no. 1, 2011, doi: 10.1371/journal.pone.0015615.
• 11.   R. Grant, L. B. L. Nguyen, and R. Breban, “Modelling human-to-human transmission of monkeypox,” Bull. World Health Organ., vol. 98, no. 9, pp. 638–640, 2020, doi: 10.2471/BLT.19.242347.
• 12.   L. D. Nolen et al., “Introduction of monkeypox into a community and household: Risk factors and zoonotic reservoirs in the democratic republic of the congo,” Am. J. Trop. Med. Hyg., vol. 93, no. 2, pp. 410–415, 2015, doi: 10.4269/ajtmh.15-0168.
• 13.   N. Fatima and K. Mandava, “Monkeypox- a menacing challenge or an endemic?,” Ann. Med. Surg., vol. 79, no. June, p. 103979, 2022, doi: 10.1016/j.amsu.2022.103979.
• 14.   E. M. Bunge et al., “The changing epidemiology of human monkeypox—A potential threat? A systematic review,” PLoS Negl. Trop. Dis., vol. 16, no. 2, pp. 1–20, 2022, doi: 10.1371/journal.pntd.0010141.
• 15.   N. I. O. Silva, J. S. de Oliveira, E. G. Kroon, G. de S. Trindade, and B. P. Drumond, “Here, there, and everywhere: The wide host range and geographic distribution of zoonotic orthopoxviruses,” Viruses, vol. 13, no. 1, 2021, doi: 10.3390/v13010043.
• 16.   A. Nalca, A. W. Rimoin, S. Bavari, and C. A. Whitehouse, “Reemergence of monkeypox: Prevalence, diagnostics, and countermeasures,” Clin. Infect. Dis., vol. 41, no. 12, pp. 1765–1771, 2005, doi: 10.1086/498155.
• 17.   S. Parker, A. Nuara, R. M. L. Buller, and D. A. Schultz, “Human monkeypox: An emerging zoonotic disease,” Future Microbiol., vol. 2, no. 1, pp. 17–34, 2007, doi: 10.2217/17460913.2.1.17.
• 18.   N. Sklenovská and M. Van Ranst, “Emergence of Monkeypox as the Most Important Orthopoxvirus Infection in Humans,” Front. Public Heal., vol. 6, no. September, pp. 1–12, 2018, doi: 10.3389/ fpubh.2018.00241.
• 19.   T. A. Sale, J. W. Melski, and E. J. Stratman, “Monkeypox: An epidemiologic and clinical comparison of African and US disease,” J. Am. Acad. Dermatol., vol. 55, no. 3, pp. 478–481, Sep. 2006, doi: 10.1016/J.JAAD.2006.05.061.
• 20.   Ramazan azim okyay, “Another Epidemic in the Shadow of Covid 19 Pandemic: A Review of Monkeypox,” Eurasian J. Med. Oncol., vol. 6, no. 2, pp. 95–99, 2022, doi: 10.14744/ejmo.2022.2022.
• 21.   C. Characteristics, E. Petersen, A. Kantele, and A. Yinka-ogunleye, “HumanMonkeypox,” vol. 33, p. 5520, 2019.
• 22.   L. A. Learned et al., “Extended interhuman transmission of monkeypox in a hospital community in the Republic of the Congo, 2003.,” Am. J. Trop. Med. Hyg., vol. 73, no. 2, pp. 428–434, Aug. 2005.
• 23.   D. Kilpatrick and H. Rouhandehi, “The Polypeptides of Monkeypox Virus:,” vol. 465, pp. 455–465, 1981.
• 24.   N. Chen et al., “Virulence differences between monkeypox virus isolates from West Africa and the Congo basin,” Virology, vol. 340, no. 1, pp. 46–63, 2005, doi: 10.1016/j.virol.2005.05.030.
• 25.   M. M. Stanford, G. McFadden, G. Karupiah, and G. Chaudhri, “Immunopathogenesis of poxvirus infections: Forecasting the impending storm,” Immunol. Cell Biol., vol. 85, no. 2, pp. 93–102, 2007, doi: 10.1038/sj.icb.7100033.
• 26.   M. Arita and I. Tagaya, “Virion polypeptides of poxviruses,” Arch. Virol., vol. 63, no. 3–4, pp. 209– 225, 1980, doi: 10.1007/BF01315028.
• 27.   D. Kahneman and A. Tversky, “No Title ,” Asp. Gen. La Planif. Tribut. En Venez., vol. 2009, no. 75, pp. 31–47, 1979.
• 28.   J. Kaler, A. Hussain, G. Flores, S. Kheiri, and D. Desrosiers, “Monkeypox: A Comprehensive Review of Transmission, Pathogenesis, and Manifestation,” vol. 14, no. 7, pp. 1–11, 2022, doi: 10.7759/cureus.26531.
• 29.   B. Moss, “Poxvirus cell entry: How many proteins does it take?,” Viruses, vol. 4, no. 5, pp. 688–707, 2012, doi: 10.3390/v4050688.
• 30.   B. Moss, “Poxvirus DNA replication,” Cold Spring Harb. Perspect. Biol., vol. 5, no. 9, 2013, doi: 10.1101/ cshperspect.a010199.
• 31.   N. Tolonen, L. Doglio, S. Schleich, and J. Krijnse Locker, “Vaccinia virus DNA replication occurs in endoplasmic reticulum-enclosed cytoplasmic mininuclei,” Mol. Biol. Cell, vol. 12, no. 7, pp. 2031–2046, 2001, doi: 10.1091/mbc.12.7.2031.
• 32.   G. C. Katsafanas and B. Moss, “Colocalization of Transcription and Translation within Cytoplasmic Poxvirus Factories Coordinates Viral Expression and Subjugates Host Functions,” Cell Host Microbe, vol. 2, no. 4, pp. 221–228, 2007, doi: 10.1016/j. chom.2007.08.005.
• 33.   Q. Kieser, R. S. Noyce, M. Shenouda, Y. C. James Lin, and D. H. Evans, “Cytoplasmic factories, virus assembly, and DNA replication kinetics collectively constrain the formation of poxvirus recombinants,” PLoS One, vol. 15, no. 1, pp. 1–22, 2020, doi: 10.1371/ journal.pone.0228028.
• 34.   E. Hammarlund et al., “Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox,” Nat. Med., vol. 11, no. 9, pp. 1005– 1011, 2005, doi: 10.1038/nm1273.
• 35.   “1 Indications and Usage JYNNEOS is a vaccine indicated for prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection. 2 Dosage and Administration For subcutaneous in,” pp. 2–12, 2019.
• 36.   J. G. Rizk, G. Lippi, B. M. Henry, D. N. Forthal, and Y. Rizk, “Prevention and Treatment of Monkeypox.,” Drugs, vol. 82, no. 9, pp. 957–963, 2022, doi: 10.1007/ s40265-022-01742-y.
• 37.   N. F. Crum-Cianflone and E. Sullivan, “Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part II,” Infect. Dis. Ther., vol. 6, no. 3, pp. 333–361, 2017, doi: 10.1007/s40121-017- 0165-y.
• 38.   Y. J. Hutin et al., “Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997.,” Emerg. Infect. Dis., vol. 7, no. 3, pp. 434–438, 2001, doi: 10.3201/eid0703.017311.
• 39.   S. N. Shchelkunov, D. N. Shcherbakov, R. A. Maksyutov, and E. V. Gavrilova, “Species-specific identification of variola, monkeypox, cowpox, and vaccinia viruses by multiplex real-time PCR assay,” J. Virol. Methods, vol. 175, no. 2, pp. 163–169, 2011, doi: 10.1016/j.jviromet.2011.05.002.
• 40.   V. A. Olson et al., “Real-Time PCR System for Detection of Orthopoxviruses and Simultaneous Identification of Smallpox Virus,” J. Clin. Microbiol., vol. 42, no. 5, pp. 1940–1946, 2004, doi: 10.1128/ JCM.42.5.1940-1946.2004.
• 41.   Y. Li, V. A. Olson, T. Laue, M. T. Laker, and I. K. Damon, “Detection of monkeypox virus with realtime PCR assays,” J. Clin. Virol., vol. 36, no. 3, pp. 194–203, 2006, doi: 10.1016/j.jcv.2006.03.012.
• 42.   K. L. Karem et al., “Characterization of acutephase humoral immunity to monkeypox: Use of immunoglobulin m enzyme-linked immunosorbent assay for detection of monkeypox infection during the 2003 north American outbreak,” Clin. Diagn. Lab. Immunol., vol. 12, no. 7, pp. 867–872, 2005, doi: 10.1128/CDLI.12.7.867-872.2005.
• 43.   M. J. Moore, B. Rathish, and F. Zahra, “Monkeypox.,” Treasure Island (FL), 2022.
• 44.   M. E. Wilson, J. M. Hughes, A. M. McCollum, and I. K. Damon, “Human monkeypox,” Clin. Infect. Dis., vol. 58, no. 2, pp. 260–267, 2014, doi: 10.1093/cid/ cit703.
• 45.   Z. Ježek, M. Szczeniowski, K. M. Paluku, and M. Mutombo, “Human Monkeypox: Clinical Features of 282 Patients,” J. Infect. Dis., vol. 156, no. 2, pp. 293–298, 1987, doi: 10.1093/infdis/156.2.293.
• 46.   M. G. Reynolds, A. M. McCollum, B. Nguete, R. S. Lushima, and B. W. Petersen, “Improving the care and treatment of monkeypox patients in low-resource settings: Applying evidence from contemporary biomedical and smallpox biodefense research,” Viruses, vol. 9, no. 12, 2017, doi: 10.3390/ v9120380.
• 47.   M. J. Stagles, “The histopathology and electroyetnz ; oscopy of a human monkeypox,” no. 44, pp. 192– 202, 1985.

Data Sharing Statement

Funding